Rexahn Pharmaceuticals, Inc. (REXN) financial statements (2020 and earlier)

Company profile

Business Address 15245 SHADY GROVE ROAD, SUITE 455
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1292720233319
Cash and cash equivalents99912101019
Short-term investments  18913230
Other undisclosed cash, cash equivalents, and short-term investments3      
Prepaid expense 110100
Other current assets0110100
Other undisclosed current assets06     
Total current assets:13162821253319
Noncurrent Assets
Property, plant and equipment0000000
Restricted cash and investments      0
Other undisclosed noncurrent assets000000 
Total noncurrent assets:0000000
TOTAL ASSETS:13162821253420
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1332321
Other undisclosed accounts payable and accrued liabilities1332321
Contract with customer, liability2 
Other undisclosed current liabilities0      
Total current liabilities:3332321
Noncurrent Liabilities
Liabilities, other than long-term debt 000000
Deferred revenue and credits00000
Deferred rent credit 0
Other undisclosed noncurrent liabilities0      
Total noncurrent liabilities:0000000
Other undisclosed liabilities 282346
Total liabilities:35124677
Stockholders' equity
Stockholders' equity attributable to parent, including:10111717192713
Common stock0000000
Treasury stock, value     (0)(0)
Additional paid in capital17316515713212411885
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)(0) 
Accumulated deficit(163)(155)(140)(115)(106)(91) 
Other undisclosed stockholders' equity attributable to parent      (73)
Total stockholders' equity:10111717192713
TOTAL LIABILITIES AND EQUITY:13162821253420

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues3      
Cost of revenue
(Cost of Goods and Services Sold)
      (0)
Gross profit:3     (0)
Operating expenses(11)(21)(17)(16)(18)(13)(8)
Other undisclosed operating income (loss)(3)     0
Operating loss:(11)(21)(17)(16)(18)(13)(8)
Nonoperating income (expense)36(8)74(5)(2)
Interest and debt expense  (1)(0)(0)(0)(0)
Net loss:(9)(14)(26)(10)(15)(19)(10)
Other undisclosed net income attributable to parent  10000
Net loss available to common stockholders, diluted:(9)(14)(25)(9)(14)(19)(9)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(9)(14)(26)(10)(15)(19)(10)
Comprehensive loss:(9)(14)(26)(10)(15)(19)(10)
Other undisclosed comprehensive income, net of tax, attributable to parent001000 
Comprehensive loss, net of tax, attributable to parent:(9)(14)(25)(9)(14)(19)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: